Apr. 5 at 5:04 PM
$ERNA Speculative take but here is a possibility: Charles Cherington has a long track record with over 50+ transactions within private equity, why would he buy in at a higher price?
Some things Ive found interesting is that Factor Bioscience engaged in a lawsuit against AstraZeneca (26th of sep 2025) and accusing them for stealing and using their mRNA and talen methods/technology including "U.S. Patent No. 11,104,888" which is licensed exclusively to
$ERNA from Factor Biosciences, they dont own it but technically they do.
AstraZeneca has a factory in Maryland which will support clinical trials and future commercial production of cell therapy treatments designed to re-engineer a patients own immunecell.
To make car-t cells you need to cut in the dna which Patent No. 11,104,888 does. Of course there is other technologies like: CRISPR-Cas9 exists but is less scalable because of the lower successrate while modifying the dna and ZFN which has high cost.
